Effetto sinergico di desferoxamina (DFO) ed eritropoietina sulla proliferazione dei precursori eritroidi nell'uremia cronica

Translated title of the contribution: Synergic effect of desferoxamine (DFO) and recombinant erythropoietin on erythroid precursors proliferation in chronic renal failure

F. Aucella, P. Scalzulli, P. Musto, M. Prencipe, G. L. Valente, M. Vigilante, M. Carotenuto, C. Stallone

Research output: Contribution to journalArticle

Abstract

Desferoxamine has been suggested to improve erythopoiesis in end-stage renal failure also independently by its aluminium - chelating effect. We yet proved the effect of DFO on erythroid precursor proliferation. In order to verify whether there may be a synergic action of DFO and r-HuEpo, we enrolled 11 patients treated by hemodialysis, free from other chronic or hematological diseases. All had a negative DFO test, very low serum Al levels, below 20 mcg/l, ferritin > 100 ng% and iPTH <200 pg/l. Samples were drawn for a basal erythroid precursors (Burst Forming Unit-Erythroid, BFU-E) evaluation: after isolation by Ficoll - Hypaque a 14-day incubation was carried out with: A) r- HuEpo 3u/ml: B) r-HuEpo 30 u/l and C) r-HuEpo 30 u/ml + DFO 167 mcg/ml. Patients then received DFO 5 mg/kg infused during the last hour of each dialysis session for 12 weeks. New BFU-E evaluations were set up after 2, 6 and 12 weeks of treatment. At the same points we also evaluated hemoglobin, ferritin transferrin, retycolocites, hypochronic erythrocites, soluble transferrin receptor and serum erythroprotein. As expected, high-dose r- HuEpo showed a higher proliferation versus low-dose r-HuEpo during all the phases of the study; interestingly, culture C yet basally showed an increased proliferation respect to cultures B: the same feature was found after 2, 6 and 12 weeks. Moreover, all studied cultures showed an increased proliferation after DFO therapy. Hemoglobin levels showed a slightly increase, such as reticolocites and sTR, while ferritin decreased. Thus, DFO increases eryhtroid precursors proliferation in chronic renal failure patients and shows a synergic effect with r-HuEpo: further investigation is needed, to ascertain whether such an effect may have clinical application.

Original languageItalian
Pages (from-to)241-247
Number of pages7
JournalGiornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia
Volume15
Issue number5
Publication statusPublished - 1998

Fingerprint

Ferritins
Erythropoietin
Chronic Kidney Failure
Erythroid Precursor Cells
Hemoglobins
Diatrizoate
Ficoll
Transferrin Receptors
Hematologic Diseases
Transferrin
Aluminum
Serum
Renal Dialysis
Dialysis
Chronic Disease
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

Effetto sinergico di desferoxamina (DFO) ed eritropoietina sulla proliferazione dei precursori eritroidi nell'uremia cronica. / Aucella, F.; Scalzulli, P.; Musto, P.; Prencipe, M.; Valente, G. L.; Vigilante, M.; Carotenuto, M.; Stallone, C.

In: Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia, Vol. 15, No. 5, 1998, p. 241-247.

Research output: Contribution to journalArticle

@article{75bfbc548f1541cf81ce0e43123c7d7f,
title = "Effetto sinergico di desferoxamina (DFO) ed eritropoietina sulla proliferazione dei precursori eritroidi nell'uremia cronica",
abstract = "Desferoxamine has been suggested to improve erythopoiesis in end-stage renal failure also independently by its aluminium - chelating effect. We yet proved the effect of DFO on erythroid precursor proliferation. In order to verify whether there may be a synergic action of DFO and r-HuEpo, we enrolled 11 patients treated by hemodialysis, free from other chronic or hematological diseases. All had a negative DFO test, very low serum Al levels, below 20 mcg/l, ferritin > 100 ng{\%} and iPTH <200 pg/l. Samples were drawn for a basal erythroid precursors (Burst Forming Unit-Erythroid, BFU-E) evaluation: after isolation by Ficoll - Hypaque a 14-day incubation was carried out with: A) r- HuEpo 3u/ml: B) r-HuEpo 30 u/l and C) r-HuEpo 30 u/ml + DFO 167 mcg/ml. Patients then received DFO 5 mg/kg infused during the last hour of each dialysis session for 12 weeks. New BFU-E evaluations were set up after 2, 6 and 12 weeks of treatment. At the same points we also evaluated hemoglobin, ferritin transferrin, retycolocites, hypochronic erythrocites, soluble transferrin receptor and serum erythroprotein. As expected, high-dose r- HuEpo showed a higher proliferation versus low-dose r-HuEpo during all the phases of the study; interestingly, culture C yet basally showed an increased proliferation respect to cultures B: the same feature was found after 2, 6 and 12 weeks. Moreover, all studied cultures showed an increased proliferation after DFO therapy. Hemoglobin levels showed a slightly increase, such as reticolocites and sTR, while ferritin decreased. Thus, DFO increases eryhtroid precursors proliferation in chronic renal failure patients and shows a synergic effect with r-HuEpo: further investigation is needed, to ascertain whether such an effect may have clinical application.",
keywords = "Chronic uremia, Desferoxamine, Erythroid precursors, Erythropoiesis",
author = "F. Aucella and P. Scalzulli and P. Musto and M. Prencipe and Valente, {G. L.} and M. Vigilante and M. Carotenuto and C. Stallone",
year = "1998",
language = "Italian",
volume = "15",
pages = "241--247",
journal = "Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia",
issn = "0393-5590",
publisher = "Wichtig Publishing Srl",
number = "5",

}

TY - JOUR

T1 - Effetto sinergico di desferoxamina (DFO) ed eritropoietina sulla proliferazione dei precursori eritroidi nell'uremia cronica

AU - Aucella, F.

AU - Scalzulli, P.

AU - Musto, P.

AU - Prencipe, M.

AU - Valente, G. L.

AU - Vigilante, M.

AU - Carotenuto, M.

AU - Stallone, C.

PY - 1998

Y1 - 1998

N2 - Desferoxamine has been suggested to improve erythopoiesis in end-stage renal failure also independently by its aluminium - chelating effect. We yet proved the effect of DFO on erythroid precursor proliferation. In order to verify whether there may be a synergic action of DFO and r-HuEpo, we enrolled 11 patients treated by hemodialysis, free from other chronic or hematological diseases. All had a negative DFO test, very low serum Al levels, below 20 mcg/l, ferritin > 100 ng% and iPTH <200 pg/l. Samples were drawn for a basal erythroid precursors (Burst Forming Unit-Erythroid, BFU-E) evaluation: after isolation by Ficoll - Hypaque a 14-day incubation was carried out with: A) r- HuEpo 3u/ml: B) r-HuEpo 30 u/l and C) r-HuEpo 30 u/ml + DFO 167 mcg/ml. Patients then received DFO 5 mg/kg infused during the last hour of each dialysis session for 12 weeks. New BFU-E evaluations were set up after 2, 6 and 12 weeks of treatment. At the same points we also evaluated hemoglobin, ferritin transferrin, retycolocites, hypochronic erythrocites, soluble transferrin receptor and serum erythroprotein. As expected, high-dose r- HuEpo showed a higher proliferation versus low-dose r-HuEpo during all the phases of the study; interestingly, culture C yet basally showed an increased proliferation respect to cultures B: the same feature was found after 2, 6 and 12 weeks. Moreover, all studied cultures showed an increased proliferation after DFO therapy. Hemoglobin levels showed a slightly increase, such as reticolocites and sTR, while ferritin decreased. Thus, DFO increases eryhtroid precursors proliferation in chronic renal failure patients and shows a synergic effect with r-HuEpo: further investigation is needed, to ascertain whether such an effect may have clinical application.

AB - Desferoxamine has been suggested to improve erythopoiesis in end-stage renal failure also independently by its aluminium - chelating effect. We yet proved the effect of DFO on erythroid precursor proliferation. In order to verify whether there may be a synergic action of DFO and r-HuEpo, we enrolled 11 patients treated by hemodialysis, free from other chronic or hematological diseases. All had a negative DFO test, very low serum Al levels, below 20 mcg/l, ferritin > 100 ng% and iPTH <200 pg/l. Samples were drawn for a basal erythroid precursors (Burst Forming Unit-Erythroid, BFU-E) evaluation: after isolation by Ficoll - Hypaque a 14-day incubation was carried out with: A) r- HuEpo 3u/ml: B) r-HuEpo 30 u/l and C) r-HuEpo 30 u/ml + DFO 167 mcg/ml. Patients then received DFO 5 mg/kg infused during the last hour of each dialysis session for 12 weeks. New BFU-E evaluations were set up after 2, 6 and 12 weeks of treatment. At the same points we also evaluated hemoglobin, ferritin transferrin, retycolocites, hypochronic erythrocites, soluble transferrin receptor and serum erythroprotein. As expected, high-dose r- HuEpo showed a higher proliferation versus low-dose r-HuEpo during all the phases of the study; interestingly, culture C yet basally showed an increased proliferation respect to cultures B: the same feature was found after 2, 6 and 12 weeks. Moreover, all studied cultures showed an increased proliferation after DFO therapy. Hemoglobin levels showed a slightly increase, such as reticolocites and sTR, while ferritin decreased. Thus, DFO increases eryhtroid precursors proliferation in chronic renal failure patients and shows a synergic effect with r-HuEpo: further investigation is needed, to ascertain whether such an effect may have clinical application.

KW - Chronic uremia

KW - Desferoxamine

KW - Erythroid precursors

KW - Erythropoiesis

UR - http://www.scopus.com/inward/record.url?scp=0031737338&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031737338&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:0031737338

VL - 15

SP - 241

EP - 247

JO - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia

JF - Giornale italiano di nefrologia : organo ufficiale della Società italiana di nefrologia

SN - 0393-5590

IS - 5

ER -